HB1539, titled the Medical Device Electronic Labeling Act, would amend the Federal Food, Drug, and Cosmetic Act to allow required labeling for medical devices, including in vitro diagnostic devices, to be provided solely by electronic means. Under the bill, electronic labeling would be permitted so long as it is readily accessible to intended users, manufacturers offer paper copies on request at no additional cost, and the device or its immediate container still bears required label information consistent with federal law and any applicable FDA order.
The bill also gives the Secretary of Health and Human Services authority to issue device-type-specific orders adding to, or creating exceptions from, the electronic-labeling requirements. Those orders would have to go through notice-and-comment procedures and could impose additional label content or conditions only if the Secretary determines they are necessary to provide reasonable assurance of safety and effectiveness. In effect, the bill expands FDA flexibility to modernize labeling requirements while preserving agency oversight and consumer access to paper information.
Impact
If enacted, the bill would revise Section 502(f) of the Federal Food, Drug, and Cosmetic Act to explicitly authorize electronic-only labeling for a broader range of medical devices. It would affect device manufacturers, including makers of in vitro diagnostics, by allowing them to rely on digital labeling systems instead of paper inserts, while still requiring paper copies upon request and maintaining certain on-device labeling obligations. The bill would also expand FDA’s rulemaking and order authority over labeling formats and conditions for specific device types.
Sentiment
The available record shows no committee transcript or vote data, so there is no documented debate or recorded sentiment beyond the bill’s introduction and referral. Based on the text, the measure appears to be a regulatory modernization bill intended to reduce paper labeling burdens while preserving safety and access safeguards. The sponsors suggest support for electronic labeling as a practical update to current device regulation.
Contention
The main potential points of contention are likely to be whether electronic-only labeling is sufficiently accessible for all intended users, especially patients or providers who may prefer or need paper instructions, and whether the FDA should have broad discretion to impose additional device-specific labeling conditions. Another possible concern is whether shifting labeling online could create compliance, usability, or safety issues for certain devices or user populations. No specific objections or supporters are identified in the available materials.